Pfizer tests new Super-Vaccine against pneumonia in chinese families
NCT ID NCT07023081
Summary
This early-stage study is testing the safety and immune response of a new 20-strain pneumococcal vaccine in healthy Chinese people of all ages, from infants to adults. The vaccine aims to protect against more strains of bacteria that cause pneumonia and other serious infections. Researchers will monitor participants for side effects and measure how well their immune systems respond to the shots.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Nanning, Guangxi, 530021, China
-
Wuming District Center for Disease Control and Prevention
Chengxiang, Nanning, 530199, China
Conditions
Explore the condition pages connected to this study.